The U.S. Food and Drug Administration (FDA) has expanded its approval for the nation’s first personalized cellular therapy for cancer, which was developed at Penn’s Abramson Cancer Center. This time, the approval includes treatment of diffuse large B-cell lymphoma (DLBCL) – the most common form of non-Hodgkin’s lymphoma – as well as high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. The approval was granted to Novartis for the chimeric antigen receptor (CAR) T-cell therapy Kymriah®. DLBCL affects approximately 30 percent of patients with NHL.
“This is an exciting event – seeing this lifesaving therapy become available widely to a large patient population with an unmet medical need,” said Stephen J. Schuster, MD, director of the Lymphoma Program at the ACC. “Many lives may be saved.”
Read more here .